Back to top

RAPT Therapeutics’ RPT904: A Promising Catalyst with Competitive Edge in the Anti-IgE Market

In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on RAPT Therapeutics, with a price target of $27.00. Emily Bo...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Rapt Therapeutics (RAPT)